The vaccine is already applied in 70 countries – including Argentina, Brazil and Mexico – in two doses separated by 21 days to people over 18 years of age and, according to clinical trials carried out, its efficacy is 91.6%.
“All the studies show that the vaccine has a good safety profile, and most of the adverse events detected were mild, no unexpected adverse events were reported during clinical studies,” Garcia said.
The Chilean government must now determine whether to include the Russian vaccine in the successful vaccination program against the virus through which 11.7 million people have already been inoculated with two doses, corresponding to 77.36% of the target population. (15.2 million out of a total of 19 million inhabitants).
To this end, Chile has so far acquired more than 27 million vaccines: 6,101,940 from Pfizer-BioNTech, 18,671,476 from Sinovac, 575,908 from CanSino and 1,713,600 from AstraZeneca. So far, Johnson & Johnson’s are not being bought.
After 16 months of pandemic, Chile relaxed health measures this week after registering the lowest numbers of infections since November.
According to the Chilean Ministry of Health, in the last 24 hours, 989 cases were registered, totaling 1,602,854 infections, while there were 42 deaths reaching a total of 34,611.